S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions

(2013) Jesse S. Voss et al.   HUMAN PATHOLOGY

The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome

(2013) Scott Robertson et al.   HUMAN PATHOLOGY

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

(2012) Armando Santoro et al.   LANCET ONCOLOGY

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

(2011) M Miyamoto et al.   BRITISH JOURNAL OF CANCER

Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors

(2011) Jesper B. Andersen et al.   GASTROENTEROLOGY

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

(2011) Anthony B. El-Khoueiry et al.   INVESTIGATIONAL NEW DRUGS

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

(2011) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

(2011) Tanios Bekaii-Saab et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells

(2010) E. Martinelli et al.   CLINICAL CANCER RESEARCH

Comparison of KRAS Mutation Analysis and FISH for Detecting Pancreatobiliary Tract Cancer in Cytology Specimens Collected During Endoscopic Retrograde Cholangiopancreatography

(2010) Benjamin R. Kipp et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort

(2010) M. Quintela-Fandino et al.   MOLECULAR CANCER THERAPEUTICS

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE